Discovery Life Sciences

Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale.    "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives."  - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2

Dr. Albert Li, Discovery’s Chief Scientific Officer, Pharmacology and Toxicology, recently published a new chapter titled “Evaluation of Metabolism-Dependent Drug Toxicity” in the Springer Nature Reference, Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. https://lnkd.in/gdafi9_k This new chapter explores how drug toxicity can increase when a parent drug is converted into more toxic metabolites through bioactivation, or decrease when transformed into less toxic metabolites through detoxification. When drug metabolism significantly impacts a drug candidate's toxicity, it may have serious complications in safety assessments. Dr. Li also discusses in vitro experimental systems that define the roles of human-specific drug metabolism on drug toxicity and explains how these systems may be applied in drug development for candidate selection to minimize safety liabilities. #DrugDiscovery #Toxicology #Pharmacology #DrugSafety

We will be exhibiting at ASHG 2024, Nov. 5-9 in Denver! Join us at booth #771 and come to our education luncheon co-hosted with Olink Proteomics on Nov. 7 at 12pm: Title: Proteomic and Genomic Biomarker Profiling Strategies: Analytical Approaches and Data Insights Across Multiple Sample Matrices    Presented by: Donald Skifter, PhD, MBA, Danielle Gutierrez, Tony (Heng) Qian, and Cynthia 辛西娅 Lawley 劳利 Click here to schedule a private meeting with our experts: https://lnkd.in/er5undXJ #ASHG24 #Genomics #Proteomics #Olink #OlinkCertifiedServiceProviders

We're thrilled to share our new research collaboration on the critical role of TEAD transcription factors in the Hippo-YAP/TAZ pathway. This project was recently presented at EORTC-NCI-AACR Symposium in Barcelona: https://lnkd.in/g9Ut5rsM Key Highlights:  - VT3989: A promising TEAD inhibitor that disrupts YAP/TAZ-TEAD interaction, showing potential to selectively block NF2-deficient mesothelioma proliferation.  - Clinical Insights: Early phase 1 trial results (NCT04665206) reveal promising partial responses in mesothelioma patients, regardless of NF2 mutation status.  - Innovative Biomarkers: Discovery's duplex IHC assay showcases a high specificity for Merlin and YAP protein expression, offering new avenues for patient stratification and therapy optimization. Check out the poster for a deep dive into these findings and their implications for future treatments. #CancerResearch #Mesothelioma #Biomarkers 

Don’t miss our two poster presentations during the World ADC Summit from November 4-7 in San Diego:   Payload in Antibody Drug Conjugates (ADCs) on Primitive Hematopoietic Progenitors Presented by Dr. Emer Clarke   Biomarker Profiling of Primary Patient Cryopreserved Tissue for Development of Ex Vivo Models   Presented by Philip McCauley #worldADC #ADC 

Meet with us at Booth #919 during the SITC in Houston. Our assay development director, Dr. Dirk Zielinski will present the following two posters: Nov 8th, Poster 857: Understanding the Role of the Immune Contexture in Invasion and Metastasis of Solid Tumors Using Multiplexed Immunofluorescence and Image Analysis   Nov 9th, Poster 1420: Using Multiplexed Immunofluorescence and Image Analysis for Categorization of Her-2 Expressing Breast Cancers Based on Signal Transduction and Immune Cell Profiles   See you in Houston! #SITC2024

OS Therapeutics’ tunable Antibody Drug Conjugate (tADC) candidate, OST-tADC-FRA-H, demonstrates strong antitumor activity in pre-clinical animal models of ovarian cancer. The folate receptor alpha (FRα)-targeting ADC uses pH-sensitive SiLinker™ technology to selectively release payloads within the acidic tumor microenvironment to reduce off-target toxicities. https://lnkd.in/gfaicnVe     Discovery supports innovative ADC research by offering clinical trial-ready, pathologist-driven biomarker assays, off-target toxicity and ADC linker stability assays, and assay-ready biospecimens. Learn more about our ADC capabilities here: https://lnkd.in/gA7nHFxD    #ADC #Oncology #Biomarkers 

Scientists conducting biomarker-driven clinical trials must carefully choose platforms, technologies, and methodologies to ensure strong early-stage performance and scalable success throughout development. Additionally, IVDR implementation has led to more delays, causing many developers to consider reducing the number of EU trial sites. Read our latest blog post to learn more: https://lnkd.in/gbacJHcD #IVDR #Biomarkers #Oncology #ClinicalTrials 

Join Discovery at booth #771 during ASHG 2024 at the Colorado Convention Center from November 5-9. Dr. Nripesh Prasad, Ph.D., our VP Scientific and Tech Development, will be presenting a poster titled “Comparison of Five different library prep kits for mRNA sequencing optimization from low input and degraded FFPE samples,” on Nov 6, from 2:30pm to 4:30pm (Board No. 1118W).  Connect with Dr. Prasad today to schedule an in-person meeting at ASHG.  #ASHG24 #Genetics #Genomics 

We are excited to meet you at the SITC annual meeting in Houston! Visit us at Booth #919 from Nov 8-9 to learn more about our biospecimen solutions and specialty lab services. You can also schedule a private meeting with our experts here: https://lnkd.in/e2rJjhuh We look forward to seeing you in Houston. #SITC2024